Immutep to Present at Healthcare Investor Conferences

Rhea-AI Summary

Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced its participation in notable investor conferences, including the 42nd Annual Cowen Health Care Conference from March 7-9, 2022, where CEO Marc Voigt will present on March 8 at 9:10 am EST. A live webcast will be available. Additionally, Immutep will engage in a fireside chat at the Maxim Growth Conference from March 28-30, 2022, set for March 28 at 11:00 am EDT. Immutep focuses on developing LAG-3 related immunotherapies for cancer and autoimmune diseases.

SYDNEY, AUSTRALIA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announces Immutep has been invited present at investor conferences, as outlined below.

42nd Annual Cowen Health Care Conference - 7 to 9 March 2022

Presenter:                               Marc Voigt, CEO of Immutep
Presentation time & date: 9:10 am – 9:40 am Eastern Standard Time (EST) on Tuesday 8 March 2022
Webcast:                                A live webcast of this event, as well as an archived recording, will be available at   https://wsw.com/webcast/cowen108/immp/2022543
1-on-1 meetings:                   Management will also be available for 1-on-1 meetings with institutional investors. Investors interested in scheduling a meeting should contact their Cowen representative.
Information:   https://www.cowen.com/conferences-and-events/42nd-annual-health-care-conference/

Maxim Growth Conference – 28 to 30 March 2022

Presenter:                                 CEO Marc Voigt will participate in a fireside chat plus corporate presentation
Fireside chat time & date:  11:00 am Eastern Daylight Time (EDT) on Monday 28 March 2022
Registration:                           https://m-vest.com/events/2022-virtual-growth-conference

About Immutep
Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.

Further information can be found on the Company’s website www.immutep.com or by contacting:

Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; tim@lifesciadvisors.com

 

FAQ

When will Immutep present at the Cowen Health Care Conference?

Immutep will present at the Cowen Health Care Conference on March 8, 2022, from 9:10 am to 9:40 am EST.

Who will represent Immutep at the investor conferences?

CEO Marc Voigt will represent Immutep at both the Cowen Health Care Conference and the Maxim Growth Conference.

What is the date of the Maxim Growth Conference presentation by Immutep?

Immutep will participate in the Maxim Growth Conference from March 28 to 30, 2022, with a presentation on March 28 at 11:00 am EDT.

What are Immutep's main areas of focus in biotechnology?

Immutep focuses on developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases.

What is the stock symbol for Immutep?

Immutep is listed under the stock symbol IMMP on NASDAQ.